10th Aug 2011 13:20
For Immediate Release | 10 August 2011 |
Alliance Pharma plc
TR-1: Notification of major interest in shares
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | Alliance Pharma plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | Yes | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | n/a | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | n/a | |||
An event changing the breakdown of voting rights | n/a | |||
Other (please specify): | On market transfer between direct and indirect funds | n/a | ||
3. Full name of person(s) subject to thenotification obligation: | NIGEL WRAY | |||
4. Full name of shareholder(s) (if different from 3.): | PERSHING NOMINEES LIMITED SMITH & WILLIAMSON NOMINEES LIMITED ROY NOMINEES LIMITED | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 9th August 2011 | |||
6. Date on which issuer notified: | 10 August 2011 | |||
7. Threshold(s) that is/are crossed orreached: | 14% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
Ordinary shares GB0031030819 | 31,119,995 | 31,119,995 | 33,619,995 | 9,455,407 | 24,164,588 | 3.95% | 10.09% | |||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
33,619,995 | 14.04% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees
Pershing Nominees Limited 9,405,407
Smith & Williamson Nominees Limited 50,000
The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited - 24,164,588
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | n/a | |
11. Number of voting rights proxy holder will ceaseto hold: | n/a | |
12. Date on which proxy holder will cease to holdvoting rights: | n/a | |
13. Additional information: | Figures are based on a total number of voting rights of 239,394,534
| |
14. Contact name: | Nigel Wray | |
15. Contact telephone number: | 020 7647 7647 | |
Related Shares:
Alliance Pharma